Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Koh Miura, Hiroshi Shima, Naoko Takebe, Julie Rhie, Kennichi Satoh, Yoichiro Kakugawa, Masayuki Satoh, Makoto Kinouchi, Kuniharu Yamamoto, Yasuhiro Hasegawa, Masaaki Kawai, Kousuke Kanazawa, Tsuneaki Fujiya, Michiaki Unno & Ryuichi Katakura. (2017) Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opinion on Drug Delivery 14:12, pages 1355-1366.
Read now
Read now
J.J.M. Kwakman & C.J.A. Punt. (2016) Oral drugs in the treatment of metastatic colorectal cancer. Expert Opinion on Pharmacotherapy 17:10, pages 1351-1361.
Read now
Read now
Omar Abdel-Rahman, Hesham ElHalawani & Shaimaa Essam-Eldin. (2016) S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines. Expert Opinion on Drug Safety 15:4, pages 437-448.
Read now
Read now
Omar Abdel-Rahman, Hesham ElHalawani & Shaimaa Essam-Eldin. (2016) S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opinion on Drug Safety 15:1, pages 5-20.
Read now
Read now
Masaaki Kawahara. (2014) Efficacy of S-1 in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 15:13, pages 1927-1942.
Read now
Read now
Yuji Miyamoto, Yasuo Sakamoto, Naoya Yoshida & Hideo Baba. (2014) Efficacy of S-1 in colorectal cancer. Expert Opinion on Pharmacotherapy 15:12, pages 1761-1770.
Read now
Read now
Taroh Satoh & Yuh Sakata. (2012) S-1 for the treatment of gastrointestinal cancer. Expert Opinion on Pharmacotherapy 13:13, pages 1943-1959.
Read now
Read now
Koh Miura, Tetsuhiko Shirasaka, Hiroki Yamaue & Iwao Sasaki. (2012) S-1 as a core anticancer fluoropyrimidine agent. Expert Opinion on Drug Delivery 9:3, pages 273-286.
Read now
Read now
Masao Kobayakawa & Yasushi Kojima. (2011) Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoTargets and Therapy 4, pages 193-201.
Read now
Read now
Kunal Roy & Partha Pratim Roy. (2009) QSAR of cytochrome inhibitors. Expert Opinion on Drug Metabolism & Toxicology 5:10, pages 1245-1266.
Read now
Read now
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
M. Nurfadhlina, K. Foong, L. K. Teh, S. C. Tan, S. Mohd Zaki & R. Ismail. (2006) CYP2A6 polymorphisms in Malays, Chinese and Indians. Xenobiotica 36:8, pages 684-692.
Read now
Read now
Articles from other publishers (88)
Heinrich Steinhoff, Miklos Acs, Sebastian Blaj, Magdolna Dank, Magdolna Herold, Zoltan Herold, Jonas Herzberg, Patricia Sanchez-Velazquez, Tim Strate, Attila Marcell Szasz & Pompiliu Piso. (2023) Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. World Journal of Gastroenterology 29:18, pages 2850-2863.
Crossref
Crossref
Yoshito Tomimaru, Hidetoshi Eguchi, Yosuke Inoue, Yuichi Nagakawa, Akihiro Ohba, Hideki Takami, Michiaki Unno, Tomohisa Yamamoto, Shoji Kawakatsu, Tsuyoshi Hayashi, Ryota Higuchi, Hirohisa Kitagawa, Satoshi Hattori, Tsutomu Fujii, Yoshiki Hirooka, Hisato Igarashi, Masayuki Kitano, Tamotsu Kuroki, Atsushi Masamune, Yasuhiro Shimizu, Masaji Tani, Satoshi Tanno, Yoshihisa Tsuji, Hiroki Yamaue, Sohei Satoi & Yoshifumi Takeyama. (2022) Impact of S‐1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real‐world data. Cancer 129:5, pages 728-739.
Crossref
Crossref
Simon Gray, Nicola de Liguori Carino, Ganesh Radhakrishna, Angela Lamarca, Richard A. Hubner, Juan W. Valle & Mairéad G. McNamara. (2022) Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology 48:6, pages 1198-1208.
Crossref
Crossref
Sheng-Xiong Zhang, Wei Liu, Bo Ai, Ling-Ling Sun, Zhe-Sheng Chen & Li-Zhu Lin. (2022) Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. Recent Patents on Anti-Cancer Drug Discovery 17:1, pages 26-41.
Crossref
Crossref
Koichi Kato, Tomoki Nakayoshi, Rika Nokura, Hiroki Hosono, Masahiro Hiratsuka, Yoshinobu Ishikawa, Eiji Kurimoto & Akifumi Oda. (2021) Deciphering Structural Alterations Associated with Activity Reductions of Genetic Polymorphisms in Cytochrome P450 2A6 Using Molecular Dynamics Simulations. International Journal of Molecular Sciences 22:18, pages 10119.
Crossref
Crossref
Albert P. Li. 2021. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity
79
137
.
Charlotte I. Stroes, Sandor Schokker, Remco J. Molenaar, Ron A. A. Mathôt, Maarten F. Bijlsma, Stephanie O. van der Woude, João P. Belo Pereira, Gerrit K. J. Hooijer, Rob H. A. Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W. van Sandick, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P. Ruurda, Sybren L. Meijer, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen & Hanneke W. M. van Laarhoven. (2021) A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers 13:4, pages 839.
Crossref
Crossref
Janthima Methaneethorn & Nattawut Leelakanok. (2020) Predictive ability of published population pharmacokinetic models of valproic acid in Thai manic patients. Journal of Clinical Pharmacy and Therapeutics 46:1, pages 198-207.
Crossref
Crossref
Jaffer A. Ajani, Milind Javle, Cathy Eng, David Fogelman, Jackie Smith, Barry Anderson, Chun Zhang & Kenzo Iizuka. (2020) Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Investigational New Drugs 38:6, pages 1763-1773.
Crossref
Crossref
Yong Chen, Yun Jiang, Jingjing Qu, Qiming Wang, Yuxian Bai, Jianhua Shi, Yehui Shi, Xue Chen, Nong Yang, Jianfu Heng & Kunyan Li. (2020) Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients. European Journal of Pharmaceutical Sciences 151, pages 105384.
Crossref
Crossref
Elizabeth C Smyth, Magnus Nilsson, Heike I Grabsch, Nicole CT van Grieken & Florian Lordick. (2020) Gastric cancer. The Lancet 396:10251, pages 635-648.
Crossref
Crossref
Ann Marie Centner, Pradeep G. Bhide & Gloria Salazar. (2020) Nicotine in Senescence and Atherosclerosis. Cells 9:4, pages 1035.
Crossref
Crossref
Thierry ConroyMichel Ducreux. (2019) Adjuvant treatment of pancreatic cancer. Current Opinion in Oncology 31:4, pages 346-353.
Crossref
Crossref
Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal & Sarfraz Ahmad. 2019. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy
57
85
.
Maike Petersen, Dieter Strack & Ulrich Matern. 2018. Annual Plant Reviews online. Annual Plant Reviews online
147
217
.
Takashi Sato. 2018. Clinical Relevance of Genetic Factors in Pulmonary Diseases. Clinical Relevance of Genetic Factors in Pulmonary Diseases
255
271
.
Letícia Leonart, João Gasparetto, Flávia Pontes, Letícia Cerqueira, Thais de Francisco & Roberto Pontarolo. (2017) New Metabolites of Coumarin Detected in Human Urine Using Ultra Performance Liquid Chromatography/Quadrupole-Time-of-Flight Tandem Mass Spectrometry. Molecules 22:11, pages 2031.
Crossref
Crossref
A Attia Ghadai, A Abou El Seoud Kamillia & S Ibrahim Abdel Rahim. (2016) Biotransformation of coumarins by Cunninghamella elegans. African Journal of Pharmacy and Pharmacology 10:18, pages 411-418.
Crossref
Crossref
Zhong-hua Chen, Su-xing Zhang, Na Long, Li-shan Lin, Tao Chen, Fei-peng Zhang, Xue-qin Lv, Pei-zhen Ye, Ning Li & Ke-zhi Zhang. (2016) An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s. Acta Pharmacologica Sinica 37:5, pages 708-718.
Crossref
Crossref
Angel Cid-Arregui. (2015) Perspectives in the treatment of pancreatic adenocarcinoma. World Journal of Gastroenterology 21:31, pages 9297.
Crossref
Crossref
Kai Hung Tiong, Nafees Ahemad Mohammed Yunus, Beow Chin Yiap, Eng Lai Tan, Rusli Ismail & Chin Eng Ong. (2014) Inhibitory Potency of 8-Methoxypsoralen on Cytochrome P450 2A6 (CYP2A6) Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21 and CYP2A6*22: Differential Susceptibility Due to Different Sequence Locations of the Mutations. PLoS ONE 9:1, pages e86230.
Crossref
Crossref
Kentaro Sudo. (2014) S-1 in the treatment of pancreatic cancer. World Journal of Gastroenterology 20:41, pages 15110.
Crossref
Crossref
Tsutomu Shimada, Norie Murayama, Hiroshi Yamazaki, Katsuhiro Tanaka, Shigeo Takenaka, Masayuki Komori, Donghak Kim & F. Peter Guengerich. (2013) Metabolic Activation of Polycyclic Aromatic Hydrocarbons and Aryl and Heterocyclic Amines by Human Cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology 26:4, pages 529-537.
Crossref
Crossref
Zhi-xiang Zhuang, Hong Zhu, Ji Wang, Min-gao Zhu, Hui Wang, Wang-yang Pu, Hua-hui Bian, Lei Chen & Hong Zhang. (2013) Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients. Acta Pharmacologica Sinica 34:4, pages 570-580.
Crossref
Crossref
Ulrich M. Zanger & Matthias Schwab. (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 138:1, pages 103-141.
Crossref
Crossref
Andy Z. X. Zhu & Rachel F. Tyndale. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
465
492
.
Junling Yang, Minxia M. He, Wei Niu, Steven A. Wrighton, Li Li, Yang Liu & Chuan Li. (2012) Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. British Journal of Clinical Pharmacology 73:2, pages 268-284.
Crossref
Crossref
Alexander V. LyubimovAnahita Bhathena & David A. Katz. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
Alexander V. LyubimovUlrich M. Zanger. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Im-Soon Lee & Donghak Kim. (2011) Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Archives of Pharmacal Research 34:11, pages 1799-1816.
Crossref
Crossref
Natasa Djordjevic, Juan Antonio Carrillo, Guillermo Gervasini, Slobodan Jankovic & Eleni Aklillu. (2010) In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. European Journal of Clinical Pharmacology 66:6, pages 571-578.
Crossref
Crossref
Kai Hung Tiong, Beow Chin Yiap, Eng Lai Tan, Rusli Ismail & Chin Eng Ong. (2010)
Functional Characterization of Cytochrome P450 2A6 Allelic Variants
CYP2A6*15
,
CYP2A6*16
,
CYP2A6*21
, and
CYP2A6*22
. Drug Metabolism and Disposition 38:5, pages 745-751.
Crossref
Crossref
S. Abe, Y. Tsuji, T. Tsushima, T. Kogawa, M. Abe, Y. Onodera, T. Mizushima, T. Kukitsu, T. Sumiyoshi, N. Yoshizaki, T. Ishii & H. Kondo. (2010) Efficacy and Feasibility of Combination Chemotherapy with S-1 and Cisplatin (2 Weeks Regimen) for Advanced Gastric Cancer. Japanese Journal of Clinical Oncology 40:4, pages 302-306.
Crossref
Crossref
Hei-Cheul Jeung, Sun Young Rha, Sang Joon Shin, Joong Bae Ahn, Sung Hoon Noh, Jae Kyung Roh & Hyun Cheol Chung. (2010) Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology 40:1, pages 29-35.
Crossref
Crossref
Max K. Leong, Yen-Ming Chen, Hong-Bin Chen & Po-Hong Chen. (2008) Development of a New Predictive Model for Interactions with Human Cytochrome P450 2A6 Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) Approach. Pharmaceutical Research 26:4, pages 987-1000.
Crossref
Crossref
Hyun Cheol Chung. (2009) Prediction of S-1-induced anemia. Gastric Cancer 12:S1, pages 23-30.
Crossref
Crossref
Jill C. Mwenifumbo & Rachel F. Tyndale. 2009. Nicotine Psychopharmacology. Nicotine Psychopharmacology
235
259
.
T. Shirasaka. (2008) Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas. Japanese Journal of Clinical Oncology 39:1, pages 2-15.
Crossref
Crossref
Dimitri Semizarov & Eric Blomme. 2008. Genomics in Drug Discovery and Development. Genomics in Drug Discovery and Development
385
421
.
Olavi Pelkonen, Miia Turpeinen, Jukka Hakkola, Paavo Honkakoski, Janne Hukkanen & Hannu Raunio. (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of Toxicology 82:10, pages 667-715.
Crossref
Crossref
Takuro Endo, Miki Nakajima, Tatsuki Fukami, Yoshiki Hara, Tomoko Hasunuma, Tsuyoshi Yokoi & Yasunori Momose. (2008) Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. Pharmacogenetics and Genomics 18:9, pages 761-772.
Crossref
Crossref
Jae-Lyun Lee & Yoon-Koo Kang. (2008) Capecitabine in the treatment of advanced gastric cancer. Future Oncology 4:2, pages 179-198.
Crossref
Crossref
Jae-Lyun Lee, Hye Jin Kang, Yoon-Koo Kang, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Hee Jung Sohn, Hawk Kim & Jung Shin Lee. (2007) Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemotherapy and Pharmacology 61:5, pages 837-845.
Crossref
Crossref
Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara, Akinori Takagane, Toshikazu Akiya, Masakazu Takagi, Kosei Miyashita, Takashi Nishizaki, Osamu Kobayashi, Wataru Takiyama, Yasushi Toh, Takashi Nagaie, Seiichi Takagi, Yoshitaka Yamamura, Kimihiko Yanaoka, Hiroyuki Orita & Masahiro Takeuchi. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet Oncology 9:3, pages 215-221.
Crossref
Crossref
Kazuhiro ARAKI, Wataru ICHIKAWA, Kenichi FUJITA, Wataru YAMAMOTO, Hisashi ENDO, Fumio NAGASHIMA, Yu SUNAKAWA, Ryuhei TANAKA, Masaru NARABAYASHI, Toshimichi MIYA, Kaori KAWARA, Yuko AKIYAMA, Yuichi ANDO & Yasutsuna SASAKI. (2008) . Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 39:4, pages 103S-104S.
Crossref
Crossref
Jane L. Yen-Revollo, Richard M. Goldberg & Howard L. McLeod. (2008) Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?. Clinical Cancer Research 14:1, pages 8-13.
Crossref
Crossref
Jill C MwenifumboRachel F Tyndale. (2007)
Genetic variability in
CYP2A6
and the pharmacokinetics of nicotine
. Pharmacogenomics 8:10, pages 1385-1402.
Crossref
Crossref
Hei-Cheul Jeung, Sun Young Rha, Hoon Kyo Kim, Ho Young Lim, Samyong Kim, Si Young Kim, Soo Jeong Gong, Chan Hee Park, Joong Bae Ahn, Sung Hoon Noh & Hyun Cheol Chung. (2007) Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. The Oncologist 12:5, pages 543-554.
Crossref
Crossref
Yonghua Wang, Yan Li & Bin Wang. (2007) An In Silico Method for Screening Nicotine Derivatives as Cytochrome P450 2A6 Selective Inhibitors Based on Kernel Partial Least Squares. International Journal of Molecular Sciences 8:2, pages 166-179.
Crossref
Crossref
Andrew X. Zhu, Jeffrey W. Clark, David P. Ryan, Jeffrey A. Meyerhardt, Peter C. Enzinger, Craig C. Earle, Charles S. Fuchs, Eileen Regan, Hiroshi Anbe, Michele Houghton, Joshua Zhang, Peter Urrea & Matthew H. Kulke. (2006) Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemotherapy and Pharmacology 59:3, pages 285-293.
Crossref
Crossref
S.P. Felter, J.D. Vassallo, B.D. Carlton & G.P. Daston. (2006) A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food and Chemical Toxicology 44:4, pages 462-475.
Crossref
Crossref
David F.V. Lewis, Yuko Ito & Brian G. Lake. (2006) Metabolism of coumarin by human P450s: A molecular modelling study. Toxicology in Vitro 20:2, pages 256-264.
Crossref
Crossref
Janne Hukkanen, Pleyton JacobIIIIII & Neal L. Benowitz. (2005) Metabolism and Disposition Kinetics of Nicotine. Pharmacological Reviews 57:1, pages 79-115.
Crossref
Crossref
Viba Malaiyandi, Edward M. Sellers & Rachel F. Tyndale. (2005) Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*. Clinical Pharmacology & Therapeutics 77:3, pages 145-158.
Crossref
Crossref
Tsutomu Shimada, Raymond L. Mernaugh & F. Peter Guengerich. (2005) Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5 enzymes. Archives of Biochemistry and Biophysics 435:1, pages 207-216.
Crossref
Crossref
Quincy Siu-Chung Chu, Lisa A. Hammond, Garry Schwartz, Leonel Ochoa, Sun-Young Rha, Louis Denis, Kathleen Molpus, Brian Roedig, Stephen P. Letrent, Bharat Damle, Arthur P. DeCillis & Eric K. Rowinsky. (2004) Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies. Clinical Cancer Research 10:15, pages 4913-4921.
Crossref
Crossref
Jeffrey D. Vassallo, Sarah M. Hicks, George P. Daston & Lois D. Lehman-McKeeman. (2004) Metabolic Detoxification Determines Species Differences in Coumarin-Induced Hepatotoxicity. Toxicological Sciences 80:2, pages 249-257.
Crossref
Crossref
Xiao-Yang He, Jian Shen, Wen-Yu Hu, Xinxin Ding, Anthony Y.H Lu & Jun-Yan Hong. (2004) Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Archives of Biochemistry and Biophysics 427:2, pages 143-153.
Crossref
Crossref
Robert L. Walsky & R. Scott Obach. (2004) VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES. Drug Metabolism and Disposition 32:6, pages 647-660.
Crossref
Crossref
Oliver von Richter, Mari?? Pitarque, Cristina Rodr??guez-Antona, Anna Testa, Roberto Mantovani, Mikael Oscarson & Magnus Ingelman-Sundberg. (2004) Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics 14:6, pages 369-379.
Crossref
Crossref
Edward F Domino, Chitoshi Kadoya, Shigeaki Matsuoka, Lisong Ni & Kari S Fedewa. (2003) Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27:6, pages 973-984.
Crossref
Crossref
G. J. Peters, P. Noordhuis, A. B. P. Van Kuilenburg, J. H. Schornagel, H. Gall, S. L. Turner, M. S. Swart, D. Voorn, A. H. Van Gennip, J. Wanders, U. Holwerda, K. Smid, G. Giaccone, P. Fumoleau & C. J. Van Groeningen. (2003) Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemotherapy and Pharmacology 52:1, pages 1-12.
Crossref
Crossref
D.F.V. Lewis, B.G. Lake, M. Dickins & P.S. Goldfarb. (2003) Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme–substrate interactions and QSARs for binding affinity and inhibition. Toxicology in Vitro 17:2, pages 179-190.
Crossref
Crossref
Anthony R Tricker. (2003) Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology 183:1-3, pages 151-173.
Crossref
Crossref
Jiro Kajita, Eiichi Fuse, Takashi Kuwabara & Hiroyuki Kobayashi. (2003) The Contribution of Cytochrome P450 to the Metabolism of Tegafur in Human Liver. Drug Metabolism and Pharmacokinetics 18:5, pages 303-309.
Crossref
Crossref
David F.V Lewis. (2003) Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Archives of Biochemistry and Biophysics 409:1, pages 32-44.
Crossref
Crossref
Rae Yuan, Soraya Madani, Xiao-Xiong Wei, Kellie Reynolds & Shiew-Mei Huang. (2002) Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions. Drug Metabolism and Disposition 30:12, pages 1311-1319.
Crossref
Crossref
Mikael Oscarson, Roman A. McLellan, Vendela Asp, MariCarmen Ledesma, Maria Luisa Bernal Ruiz, Blanca Sinues, Arja Rautio & Magnus Ingelman-Sundberg. (2002) Characterization of a novelCYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Human Mutation 20:4, pages 275-283.
Crossref
Crossref
Pailin Ujjin, Soisungwan Satarug, Yuvaree Vanavanitkun, Satoshi Daigo, Noritaka Ariyoshi, Hiroshi Yamazaki, Paul E. B. Reilly, Michael R. Moore & Tetsuya Kamataki. (2002) Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics 12:3, pages 241-249.
Crossref
Crossref
Lisa A Howard, Edward M Sellers & Rachel F Tyndale. (2002) The role of pharmacogenetically-variable cytochrome P450 enzymes in. Pharmacogenomics 3:2, pages 185-199.
Crossref
Crossref
Wenjiang Zhang, Yamini Ramamoorthy, Tansel Kilicarslan, Helma Nolte, Rachel F. Tyndale & Edward M. Sellers. (2002) Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives. Drug Metabolism and Disposition 30:3, pages 314-318.
Crossref
Crossref
Rachel F. Tyndale & Edward M. Sellers. (2002) Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior. Therapeutic Drug Monitoring 24:1, pages 163-171.
Crossref
Crossref
G. J. Peters, C. J. van Groeningen, G. Giaccone & Robert M. WhiteJrJr. (2001) Fluorouracil (5FU) Pharmacokinetics in 5FU Prodrug Formulations With a Dihydropyrimidine Dehydrogenase Inhibitor. Journal of Clinical Oncology 19:22, pages 4267-4269.
Crossref
Crossref
Hannu Raunio, Arja Rautio, Harriet Gullstén & Olavi Pelkonen. (2001) Polymorphisms of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology 52:4, pages 357-363.
Crossref
Crossref
Wen Tan, Gen-Fu Chen, De-Yin Xing, Chun-Ying Song, Fred F. Kadlubar & Dong-Xin Lin. (2001) Frequency ofCYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. International Journal of Cancer 95:2, pages 96-101.
Crossref
Crossref
Cyrus P. Zabetian, Joel Gelernter & Joseph F. Cubells. (2000) Functional variants atCYP2A6: New genotyping methods, population genetics, and relevance to studies of tobacco dependence. American Journal of Medical Genetics 96:5, pages 638-645.
Crossref
Crossref
Olavi Pelkonen, Arja Rautio, Hannu Raunio & Markku Pasanen. (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:1-3, pages 139-147.
Crossref
Crossref
Mikael Oscarson, Roman A. McLellan, Harriet Gullstén, José A.G. Agúndez, Julio Benı́tez, Arja Rautio, Hannu Raunio, Olavi Pelkonen & Magnus Ingelman-Sundberg. (1999)
Identification and characterisation of novel polymorphisms in the
CYP2A
locus: implications for nicotine metabolism
. FEBS Letters 460:2, pages 321-327.
Crossref
Crossref
Pavel Souček. (1999) Novel sensitive high-performance liquid chromatographic method for assay of coumarin 7-hydroxylation. Journal of Chromatography B: Biomedical Sciences and Applications 734:1, pages 23-29.
Crossref
Crossref
Pavel Souček. (1999) Expression of Cytochrome P450 2A6 in Escherichia coli: Purification, Spectral and Catalytic Characterization, and Preparation of Polyclonal Antibodies. Archives of Biochemistry and Biophysics 370:2, pages 190-200.
Crossref
Crossref
Kyoko Kitagawa, Naoki Kunugita, Takahiko Katoh, Mihi Yang & Toshihiro Kawamoto. (1999) The Significance of the Homozygous CYP2A6 Deletion on Nicotine Metabolism: A New Genotyping Method of CYP2A6 Using a Single PCR–RFLP. Biochemical and Biophysical Research Communications 262:1, pages 146-151.
Crossref
Crossref
Mikael Oscarson, Roman A McLellan, Harriet Gullstén, Qun-Ying Yue, Matti A Lang, Maria Luisa Bernal, Blanca Sinues, Ari Hirvonen, Hannu Raunio, Olavi Pelkonen & Magnus Ingelman-Sundberg. (1999)
Characterisation and PCR‐based detection of a
CYP2A6
gene deletion found at a high frequency in a Chinese population
. FEBS Letters 448:1, pages 105-110.
Crossref
Crossref
B.G Lake. (1999) Coumarin Metabolism, Toxicity and Carcinogenicity: Relevance for Human Risk Assessment. Food and Chemical Toxicology 37:4, pages 423-453.
Crossref
Crossref
D.F.V Lewis, M Dickins, B.G Lake, P.J Eddershaw, M.H Tarbit & P.S Goldfarb. (1999) Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 133:1, pages 1-33.
Crossref
Crossref
Hiroshi Yamazaki, Masaaki Tanaka & Tsutomu Shimada. (1999) Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. Journal of Chromatography B: Biomedical Sciences and Applications 721:1, pages 13-19.
Crossref
Crossref
Mikael Oscarson, Harriet Gullstén, Arja Rautio, Maria Luisa Bernal, Blanca Sinues, Marja-Liisa Dahl, Jari H Stengård, Olavi Pelkonen, Hannu Raunio & Magnus Ingelman-Sundberg. (1998)
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine
C
‐oxidase
. FEBS Letters 438:3, pages 201-205.
Crossref
Crossref
Michel Andréjak, Marta Gersberg, Catherine Sgro, Guillaume Decocq, Jean-Dominique Hamel, Michelle Morin & Valérie Gras. (1998) French pharmacovigilance survey evaluating the hepatic toxicity of coumarin. Pharmacoepidemiology and Drug Safety 7:S1, pages S45-S50.
Crossref
Crossref
M. Teresa Donato, José V. Castell & Maria José Gómez-Lechón. (2020) The Coumarin 7-Hydroxylation Microassay in Living Hepatic Cells in Culture. Alternatives to Laboratory Animals 26:2, pages 213-223.
Crossref
Crossref